Wound Healing Outcomes and Health-Related Quality-of-Life Changes in the ACHILLES Trial 1-Year Results From a Prospective Randomized Controlled Trial of Infrapopliteal Balloon Angioplasty Versus Sirolimus-Eluting Stenting in Patients With Ischemic Peripheral Arterial Disease by Katsanos, Konstantinos et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 1 0 . 0 3 8PERIPHERALWound Healing Outcomes and
Health-Related Quality-of-Life Changes
in the ACHILLES Trial
1-Year Results From a Prospective Randomized Controlled Trial
of Infrapopliteal Balloon Angioplasty Versus Sirolimus-Eluting
Stenting in Patients With Ischemic Peripheral Arterial DiseaseKonstantinos Katsanos, MSC, MD, PHD,a,b Stavros Spiliopoulos, MD, PHD,b Athanasios Diamantopoulos, MD, PHD,a
Dimitris Siablis, MD, PHD,b Dimitris Karnabatidis, MD, PHD,b Dierk Scheinert, MDcABSTRACTFro
Pa
Rio
con
Ga
rep
MaOBJECTIVES The authors sought to report the wound healing outcomes, health-related quality-of-life changes and
quality-adjusted life-years (QALYs) gain in the 2 treatment arms of the ACHILLES (Comparing Angioplasty and DES in the
Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease) multicenter randomized trial.
BACKGROUND The ACHILLES randomized trial has previously shown that sirolimus-eluting stents (SES) may achieve
lower vessel restenosis and higher event-free survival rates compared with plain balloon angioplasty (PTA) for infra-
popliteal lesions.
METHODS A total of 200 patients were randomly assigned between SES and PTA for the treatment of infrapopliteal
arterial occlusive lesions. Progression of wound healing was serially assessed by digital photography. Health-related
quality-of-life scores were assessed with the self-administered EQ-5D questionnaire up to 1 year from randomization.
QALYs gained were calculated with a standard multiplicative model using distribution-free Bayesian modeling.
RESULTS In total, 109 open wounds (n ¼ 54 in SES; n ¼ 55 in PTA) were documented at baseline. At 6 months, wound
volume reduction (%) was signiﬁcantly higher in the SES group (95% healing [95% conﬁdence interval (CI): 80% to 99%]
comparedwith60%healing [95%CI: 13%to90%] in thePTAgroup; p¼0.048). At 1 year, rates of completewound closure
were higher in the case of SES (72.9% vs. 55.6% closed wounds in PTA; p ¼ 0.088). The recorded weighted EQ-5D score
improved signiﬁcantly up to 1 year in case of SES (p < 0.0001), but not in case of PTA. There was a trend of more QALYs
gained with SES compared with PTA up to 1 year after randomization. Relative QALY gain was 0.10 (95% CI:0.01 to 0.21;
p ¼ 0.08) in the whole study and 0.17 (95% CI: 0.03 to 0.35; p ¼ 0.09) in the wound subgroups comparison.
CONCLUSIONS Infrapopliteal SES accelerates wound healing and may improve quality of life compared with PTA.
(Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease [ACHILLES];
NCT00640770) (J Am Coll Cardiol Intv 2016;9:259–67) © 2016 by the American College of Cardiology Foundation.m the aDepartment of Interventional Radiology, Guy’s and St. Thomas’ Hospitals, NHS Foundation Trust, King’s Health
rtners, London, United Kingdom; bDepartment of Interventional Radiology, Patras University Hospital, School of Medicine,
n, Greece; and the cDepartment of Angiology, Park Hospital and Universitätsklinikum, Leipzig, Germany. Dr. Scheinert is a
sultant for and/or member of scientiﬁc advisory board of Abbott, Biotronik, Boston Scientiﬁc, Cook Medical, Cordis, CR Bard,
rdia Medical, Medtronic/Covidien, TriRemeMedical, Trivascular, and Upstream Peripheral Technologies. All other authors have
orted that they have no relationships relevant to the contents of this paper to disclose.
nuscript received August 6, 2015; revised manuscript received October 14, 2015, accepted October 22, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
CLI = critical limb ischemia
EuroQoL EQ-5D = 5-D system
HRQOL = health-related
quality of life
ITT = intent-to-treat
PROMS = patient-reported
outcome measures
PTA = plain balloon
angioplasty/percutaneous
transluminal angioplasty
QALY = quality-adjusted
life-year
RCT = randomized controlled
trial
SES = sirolimus-eluting
stent(s)
TLR = target lesion
revascularization
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260T he incidence of critical limb ischemia(CLI) in the Western population isestimated between 500 to 1,000 per
1,000,000 persons per annum, but is antici-
pated to rise mainly due to the continuously
increasing incidence of diabetes and progres-
sive increase of life expectancy in the devel-
oped world countries (1,2). Ischemic foot
ulcers typically develop in end-stage CLI,
resulting in minor or major tissue loss and
are the main cause of major amputations,
especially if no revascularization is attempted
(3). Infrapopliteal arterial occlusive disease
is a leading cause of CLI, and recent deve-
lopments in percutaneous endovascular
treatment of CLI included 3 multicenter ran-
domized controlled trials (RCT); the YUKON-
BTX (YUKON-Drug-Eluting Stent Below the
Knee-Randomised Double-Blind Study),
the DESTINY (Drug Eluting Stents in the
Critically Ischemic Lower Leg), and theACHILLES (Comparing Angioplasty and DES in
the Treatment of Subjects With Ischemic Infrapopli-
teal Arterial Disease) trials, which have provided Class
1, Level of Evidence: A, about the safety and clinical
effectiveness of infrapopliteal placement of drug-
eluting stents (4–7).SEE PAGE 268The ACHILLES prospective multicenter RCT was
the only one among the aforementioned studies that
compared the performance of drug-eluting stents
(CYPHER SELECT sirolimus-eluting stent [SES]; Cor-
dis, Johnson & Johnson, Bridgewater, New Jersey)
with the well-established percutaneous transluminal
balloon angioplasty (PTA) in infrapopliteal ischemic
arterial disease (5). In total, 200 patients were ran-
domized between SES and PTA for the treatment of
infrapopliteal arterial lesions at 16 European in-
stitutions. The study was designed and powered us-
ing 1-year angiographic in-segment binary restenosis
assessed by quantitative analysis as the primary
endpoint. The previously published 1-year analysis
reported signiﬁcantly lower angiographic vascular
restenosis (22.4% vs. 41.9%; p ¼ 0.019) and higher
vessel patency (75.0% vs. 57.1%; p ¼ 0.025), but rates
of index-limb amputation, patient death, target limb
revascularization (TLR), and Rutherford class changes
were largely similar in the SES and PTA groups at 1
year. Nonetheless, patients treated with infrapopli-
teal SES experienced a signiﬁcantly improved overall
event-free survival (p ¼ 0.028 compared with PTA),
which was a post-hoc composite survival endpointdeﬁned as freedom from death, TLR, bypass/ampu-
tation, and Rutherford class $4) (5).
The ACHILLES protocol included also the docu-
mentation of further important clinical variables such
as index-limb wound status and the recording of
health-related quality-of-life (HRQOL) parameters.
Progression of wound healing and serial changes of
HRQOL outcomes were not reported in the initial
report because these data were scheduled to be
collated, analyzed, and published separately. The au-
thors herein report the ﬁnal 1-year results from the
wound healing outcomes and HRQOL changes from
the ACHILLES multicenter RCT to provide a more
comprehensive consideration of the treatment effect
of SES compared with PTA in the infrapopliteal
arteries.METHODS
STUDY DESIGN. The ACHILLES multicenter RCT
was registered in a public electronic database
(NCT00640770), and its design, material andmethods,
and angiographic and clinical results have been pub-
lished previously in great detail (5). Brieﬂy, randomi-
zation was performed on a 1:1 basis using a
numbered envelope system, and both severe inter-
mittent claudication and CLI patients were recruited
in the study (Rutherford-Becker class 3 to 5; #2
lesions with $70% stenosis, maximum lesion
length #120 mm). In total, 99 patients (113 lesions)
were assigned to SES placement, and 101 patients
(115 lesions) to standard PTA treatment. Baseline
demographics and lesions characteristics were
evenly distributed between the 2 groups, and
average treated lesion length was nearly 29 mm in
both cases. Eight cases crossed over from PTA to
SES treatment because of a suboptimal angioplasty
result. After the index procedure, all participants
received low-dose aspirin, and SES subjects were
also prescribed standard dose thienopyridine treat-
ment (clopidogrel or ticlopidine) for 6 months. After
1 year of follow-up, 74 patients were evaluable in the
SES group and 80 patients in the PTA group.
WOUND HEALING ASSESSMENT. The assessment of
wound healing was pre-speciﬁed in the original pro-
tocol. Index-limb wound status was assessed at base-
line and at pre-scheduled follow-up visits at 6 weeks,
6 months, and 12 months following the index proce-
dure. Digital photographs of the wounds were taken
before the index procedure and on each follow-up visit
with a dedicated 1-cm2 graded metallic frame to assess
progress of wound healing. All wounds were reviewed
and evaluated by a diabetic foot specialist acting as
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261an independent reviewer, who was blinded to initial
treatment allocation. Quantitative volumetric analysis
of wound healing progress was performed to allow
for objective comparison between the 2 study arms.
Wound status reports included pre-determinedwound
codes for the anatomic location of the index wound on
the target limb, assessment of local infection, and re-
view of wound closure status at different time points.
All amputations were classiﬁed by the investiga-
tional sites and adjudicated by the clinical events
committee with all clinical documentation available
(e.g. operation report, photograph). A minor ampu-
tation was deﬁned as any amputation involving
removal of a toe or part of the foot (Level 1). A wound
that was healed within 30 days following a minor
amputation was considered “closed.” Once a wound
was adjudicated as “closed” in one assessment, and
wound healing information was missing at a later
follow-up time point, the status “closed” was carried
forward if there was no repeat revascularization be-
tween the 2 follow-up time points. Conversely, once a
wound was adjudicated as “not closed,” and wound
status information was missing at a later follow-up
time point, then the wound status information was
considered as missing at the later time point.
HEALTH-RELATED QUALITY OF LIFE. HRQOL utility
scores were assessed using a self-administered
EuroQoL 5-D system (EQ-5D) with higher scores
indicating improved health and well-being as sub-
jectively perceived by each patient. All subjects were
asked to provide HRQOL data up to 1 year following
randomization regardless of the presence of tissue
loss at baseline or amputation at follow-up. The EQ-
5D questionnaire is designed to evaluate different
health parameters, including mobility, self-care,
everyday activities, pain or discomfort, and anxiety
or depression (EuroQol health dimensions), using 3
ordinal levels (EuroQol health scoring system: “no
problems,” “some problems,” or “extreme problems/
unable to”) for each dimension. The EQ-5D scores
were then adapted into a preference-based, single
weighted, utility score (EQ-5D score) using the time
trade-off method as described elsewhere (8,9).
Aforementioned patient-reported outcome measures
(PROMS) were recorded at screening (before the pro-
cedure) and at 6 weeks, 6 months, and 12 months
after the index procedure.
QUALITY-ADJUSTED LIFE-YEARS. Quality-adjusted life-
years (QALYs) were calculated for each group at each
time interval (0 to 6 weeks, 6 weeks to 6 months, 6
months to 12 months) with a standard multiplicative
model using the calculated group-speciﬁc EQ-5D
score relating to each time interval (8). CumulativeQALY scores of each study arm for every time point
were calculated by summation of individual time-
speciﬁc QALYs over the duration of the trial. Some
PROMS data (individual domains and weighted EQ-5D
score) were missing either because trial participants
died or did not complete the questionnaires or were
lost from follow-up. Overall, PROMS data were
missing because of attrition in 17.6% of the cases (5.5%
at screening, 13.5% at 6 weeks, 23.5% at 6 months, and
28.0% at 12 months). Because of nonnormal heavily
right-sided skewed distributions of PROMS data in
both groups at the various time points, all QALY cal-
culations and pairwise comparisons were performed
with noninformative distribution-free Markov Chain
Monte Carlo simulation (MCMC with Gibbs sampling;
WinBUGS version 1.4.3, MRC Biostatistics Unit,
Cambridge, United Kingdom).
STATISTICAL ANALYSIS. All data including patients’
demographics, procedural details, electronic photo
ﬁles, wound status and HRQOL reports, were referred
from all 16 centers to a contract research organization
(Clinquest Europe, Leiden, the Netherlands) where
data management and analysis was performed inde-
pendently from the study sponsor (Cordis, Johnson &
Johnson). Amassed data were provided by Cordis
Corporation and analyzed independently from the
company without any direct sponsorship or funding
for the purposes of this analysis. Descriptive statistics
were used for all baseline, lesion, and procedural
variables. Categorical variables were expressed as
counts (percentages), and continuous variables were
given as medians with interquartile ranges (i.e., be-
tween the 25th and 75th percentiles) or as mean  SD
if they passed the Kolmogorov-Smirnov goodness-of-
ﬁt normality test. The unpaired Student t test was
used to test normally distributed continuous vari-
ables; the Mann-Whitney U test was used for
nonparametric continuous variables. The Kruskal-
Wallis test was used for nonparametric testing of
multiple group comparisons. Comparison of pro-
portions was done by testing the null hypothesis that
the proportions were equal and the chi-square test (or
the Fisher exact test in case of single-digit event
counts) was applied in case of cumulative analysis.
Event-speciﬁc adjusted denominators were applied
for reporting of cumulative event rates up to 360 days
following the index procedure. All outcome measures
were analyzed on both an intent-to-treat (ITT) and as-
treated basis (10). The threshold of statistical signiﬁ-
cance was set at alpha <0.05. Statistical analysis was
performed with the GraphPad Prism statistical soft-
ware package (version 5, GraphPad Software, La Jolla,
California). Bayesian modeling for distribution-free
TABLE 1 Patient Demographics and Procedural Variables
SES Group
(n ¼ 99 Pts
With n ¼ 113 Lesions)
PTA Group
(n ¼ 101 Pts
With n ¼ 115 Lesions) p Value
All randomized patients
Baseline demographics
Age, yrs 72.4  9.4 74.3  8.2 0.117
Males 67/99 (67.7) 76/101 (75.2) 0.274
Diabetes 64/99 (64.6) 65/101 (64.4) 1.000
History of PAD 66/99 (66.7) 64/101 (63.4) 0.658
History of CAD 45/99 (45.5) 45/101 (44.6) 1.000
Hypertension 89/99 (89.9) 92/101 (91.1) 0.813
Hyperlipidemia 77/99 (77.6) 69/101 (68.3) 0.154
Smokers 38/99 (38.4) 27/101 (26.3) 0.094
Procedural variables
Total lesion length, mm 26.9  20.9 26.8  21.3 0.913
Chronic total occlusions 92/113 (81.3) 82/115 (71.4) 0.334
Pre-procedure stenosis, % 68.8  19.3 74.0  19.0 0.039
Post-procedure stenosis, % 13.3  14.3 25.9  15.2 <0.001
Binary restenosis at 1 year 15/67 (22.4) 31/74 (41.9) 0.019
Major amputations 3/80 (3.75) 3/85 (3.53) 1.000
Minor amputations 8/80 (10.0) 14/85 (16.5) 0.257
Patients with baseline wounds n ¼ 41 Pts
With 54 Wounds
n ¼ 37 Pts
With 55 Wounds
Baseline demographics
Age, yrs 72.2  10.2 74.2  8.58 0.347
Males 29/41 (70.7) 32/37 (86.5) 0.108
Diabetes 28/41 (68.3) 32/37 (86.5) 0.066
History of PAD 5/41 (12.2) 3/37 (8.1) 0.712
History of CAD 15/41 (36.6) 12/37 (32.4) 0.813
Hypertension 36/41 (87.8) 36/37 (97.3) 0.204
Hyperlipidemia 33/40 (82.5) 21/37 (56.8) 0.024
Smokers 13/41 (31.7) 7/36 (19.4) 0.299
Procedural variables
Total lesion length, mm 25.5  13.6 32.3  24.4 0.347
Chronic total occlusions 35/41 (85.4) 25/37 (67.6) 0.105
Pre-procedure stenosis, % 68.5  19.1 79.3  17.7 0.019
Post-procedure stenosis, % 19.3  9.49 28.9  11.2 <0.001
Binary restenosis at 1 year 7/25 (28.0) 15/23 (65.2) 0.019
Major amputations 3/41 (7.3) 3/37 (8.1) 1.000
Minor amputations 7/41 (17.1) 12/37 (32.4) 0.186
Values are mean  SD or n/N (%).
CAD ¼ coronary artery disease; PAD ¼ peripheral artery disease; PTA¼ plain balloon angioplasty/percutaneous
transluminal angioplasty; Pts ¼ patients; SES ¼ sirolimus-eluting stent(s).
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262calculation and comparison of wound healing per-
centages and QALYs differences between SES and PTA
groups was done with a Gibbs sampler and Bayesian
p values and 95% credible intervals are reported
(WinBUGS version 1.4.3; code available on request).
RESULTS
PATIENT CHARACTERISTICS. A total of 109 open
wounds were observed at baseline and evaluated per
protocol at all follow-up time points. At baseline, 54
open wounds were recorded in 41 subjects in the SES
arm (41 of 99; 41.4%) and 55 open wounds in 37subjects in the PTA arm (37 of 101; 36.6%). Baseline
demographics of the open wound patient cohorts
were well balanced and in line with the characteris-
tics of the overall patient groups (Table 1). Discor-
dance was noted only in case of hyperlipidemia (well
matched in the whole RCT, but signiﬁcantly higher in
the SES wound subgroup compared with the PTA
wound subgroup) and a trend in case of diabetes
(numerically more frequent in the PTA wound sub-
group compared with the SES wound subgroup) as
outlined in detail in Table 1. Pre-procedure target
lesion stenosis was signiﬁcantly higher in the PTA
group both when analyzing the whole randomized
study and the wound subgroups separately. Up to 1
year, comparative analysis of the angiographic and
clinical ﬁndings in the wound cohorts yielded similar
results with the overall study; post-procedure resid-
ual stenosis was signiﬁcantly less in the SES group
(19.3  9.49% compared with 28.9  11.2% in the PTA
group; p < 0.001), as well as binary restenosis of an-
giographically evaluable lesions at 1 year (7 of 25
[28.0%] in the SES arm compared with 15 of 23 [65.2%]
in the PTA arm; p ¼ 0.019). Minor and major ampu-
tations were largely similar in the wound subgroups
analysis and represented the majority of the ampu-
tations recorded in the ACHILLES study (Table 1).
WOUND HEALING OUTCOMES. Rates of closed
wounds increased consistently throughout the whole
follow-up period in both treatment groups. When
analyzed per ITT, patients treated with SES had 25.9%
of wounds closed by 6 weeks following stent place-
ment, 54.2% closed at 6 months, and 72.3% closed at 1
year follow-up. For comparison, wound closure rates
in the PTA control arm were 20.0%, 46.9%, and
56.5%, respectively. None of these differences were
statistically signiﬁcant (p ¼ 0.501, p ¼ 0.544,
p ¼ 0.132), although a trend was noted in favor of the
SES arm at 1 year. There were no differences in wound
healing outcomes among different randomization
canters (analysis of variance p ¼ 0.29). At 1 year, the
relative risk of complete wound healing was 1.29 (95%
conﬁdence interval [CI]: 0.83 to 2.00) between the
SES and PTA arms when including the treatment
center as a random effect to account for potential
healthcare variations across different randomization
sites (I2 heterogeneity: 15.2%). In the “as-treated”
group comparison to account for crossovers, results
were similar, but the difference at 1 year was more
pronounced in favor of the SES, albeit also not sta-
tistically signiﬁcant (72.9 vs. 55.6% closed wounds;
p ¼ 0.088). For more details, please see Figure 1.
Figure 2 demonstrates the ITT results of the
volumetric quantitative analysis of wound healing
progression that showed better results in case of the
FIGURE 1 Wound Healing Outcomes in the ACHILLES Randomized Trial
Results are reported at different time points following both the ITT and the “as treated” analysis. ITT ¼ intent to treat; PTA ¼ plain balloon
angioplasty/percutaneous transluminal angioplasty; SES ¼ sirolimus-eluting stent(s).
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263SES-allocated patients. Absolute reduction of wound
volumes (cm3) was numerically higher both at 6
weeks and at 6 months in the SES arm compared with
the PTA arm. Adjusted percentage reduction of
wound volumes (% healing) demonstrated similar
differences in favor of the SES group at 6 weeks and at
6 months; the latter being signiﬁcantly better (95%
healing [95% CI: 80% to 99%] in the SES-treated limbs
compared with 60% healing [95% CI: 13% to 90%] in
the PTA cases; p ¼ 0.048). At 1 year, SES- and PTA-
treated wounds showed very similar results in terms
of progression of wound healing (Figure 2).
HRQOL OUTCOMES. HRQOL outcomes were analyzed
and compared between SES and PTA ﬁrst for the
whole-trial arms (N ¼ 200) and second for theFIGURE 2 Volumetric Analysis of Wound Healing in the SES and PTA
Progression of wound healing was quantiﬁed in both absolute (cm3 volu
an ITT basis. Abbreviations as in Figure 1.subgroups of patients with recorded wounds at
baseline (n ¼ 78; post-hoc wound cohort analysis).
Overall, there was an improvement in most of the
individual domains of the captured EQ-5D data.
Recorded changes were more prominent in the do-
mains of “mobility” and “pain,” and to a lesser extent
in the domain of “anxiety,” whereas no notable dif-
ferences were noted in the domains of “self-care” and
“activity.” Most of the improvement in the quality-of-
life variables was noted within the ﬁrst 6 weeks
following the revascularization procedure, but there
were no signiﬁcant differences when comparing in-
dividual PROMS domains between the 2 treatments
under investigation (SES vs. PTA) (Figure 3). Calcu-
lated weighted EQ-5D scores showed some improve-
ment over time in both groups, which again was moreWound Subgroups
me reduction) and relative terms (adjusted % volume reduction) on
FIGURE 3 Recorded HRQOL Domains Using a Self-Administered EQ-5D
Columns display the patient ratio reporting at least some problems (i.e., “some problems” or “extreme problems/unable to”) for each of the
5 domains included in the EuroQoL 5-D system (EQ-5D) instrument (mobility, self-care, activities, pain, and anxiety). HRQOL ¼ health-related
quality of life; other abbreviations as in Figure 1.
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264pronounced within the ﬁrst 6 weeks after treatment.
However, multiple group comparison showed that
this pattern of improvement was highly statistically
signiﬁcant only in the SES group (p < 0.0001 on ITT
analysis). Largely similar ﬁndings in terms of overall
quality-of-life improvement were found when
analyzing separately only the subgroups of patients
with wounds at baseline (wound cohort subgroup
analysis; p ¼ 0.02 on ITT analysis) (Figure 4).
QALY GAINS. Compared with baseline, infrapopliteal
SES placement produced statistically signiﬁcant
QALY gains at all 3 different time points (6 weeks,
6 months, and 12 months), whereas in the PTA group,QALY gains were signiﬁcant only up to 6 months.
Furthermore, the SES group exhibited a steady gain
of QALYs throughout the 1-year follow-up period,
compared with only minor gains in the PTA group up
to 6 months. In the SES group, 0.13 (95% CI: 0.05 to
0.21) QALYs were gained at 1 year after randomization
compared with 0.03 (95% CI: 0.06 to 0.11) in the PTA
control group. Head-to-head comparisons between
the SES and PTA groups demonstrated a relative gain
of 0.10 (95% CI: 0.01 to 0.21) QALYs in favor of the
SES group at 1 year (p ¼ 0.08). The relative QALY
gains were more pronounced in favor of the SES
group when focusing on the wound subgroups. In the
SES group, 0.22 (95% CI: 0.09 to 0.36) QALYs were
FIGURE 4 Weighted EQ-5D Scores in the ACHILLES Randomized Trial
Results are reported at different time points on an ITT basis for both the overall trial and for the wound subgroups separately. Abbreviations
as in Figures 1 and 3.
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265gained at 1 year after randomization compared with
0.06 (95% CI: 0.08 to 0.19) in the PTA control group.
Head-to-head subgroup comparisons demonstrated a
relative gain of 0.17 (95% CI: 0.03 to 0.35) QALYs in
favor of the SES wound cohort at 1 year with a trend
towards signiﬁcance (p ¼ 0.09) (Figure 5).
DISCUSSION
Generic HRQOL tools are frequently used as sec-
ondary outcome measures in randomized trials to
assess the perceived health improvement and to
allow clinically relevant cost-utility analysis. Typi-
cally, quality of life is depressed in diabetes and
further impaired by the presence of diabetic foot ul-
cers. On the other hand, successful wound healing
is associated with improvements in HRQOL (11,12).FIGURE 5 QALYs Gained in the ACHILLES Randomized Trial
Results are reported at different time points on an ITT basis for both the
adjusted life-year; other abbreviations as in Figure 1.Over the past decade, several studies including
multicenter randomized trials provided evidence
demonstrating the superiority of below-the-knee
drug-eluting stenting compared with PTA or bare-
metal stenting in terms of both angiographic and
clinical endpoints (13). To our knowledge, this is the
ﬁrst report of wound healing outcomes and HRQOL
outcomes following balloon angioplasty and drug-
eluting stent placement in the infrapopliteal arteries.
The ACHILLES RCT has previously reported
compelling evidence of reduced vascular restenosis
and improved overall event-free survival in favor of
sirolimus-eluting stents compared with PTA as the
control group. The authors have herein further re-
ported on the wound healing outcomes of patients
with tissue loss at baseline and have shown a clear
beneﬁt of SES over PTA. Progression of woundoverall trial and for the wound subgroups separately. QALY ¼ quality-
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266healing was signiﬁcantly accelerated in the SES allo-
cated limbs (up to 6 months) and ﬁnal complete
wound closure rates were higher at 1-year follow-up.
In order to attain precise and unbiased outcomes,
wound healing assessment was performed and adju-
dicated by an independent diabetic foot specialist
blinded to initial treatment allocation. In addition,
wound volumes were quantiﬁed to allow a more
robust comparison of the healing process. Results
from the ACHILLES wound cohorts suggest that more
than two-thirds of the patients treated with SES will
experience complete wound healing within 1 year
from the baseline procedure compared with around
half of the patients treated with PTA. Of further
interest, in case of infrapopliteal SES placement most
of the wound healing progress will take place within
the ﬁrst 6 months from treatment compared with
more delayed healing up to 1 year in case of PTA.
Accelerated wound healing could be theoretically
associated with reduced risk of infection and also
reduced health care costs (e.g., shorter duration of
wound care needed). Successful wound healing has
been previously related with improved HRQOL rat-
ings (10,14). On the other hand, low reported HRQOL
has been found to correlate with future major
amputations and death (15).
In the ACHILLES trial, HRQOL was measured using
the self-administered EQ-5D questionnaire, which is
an established, easy-to-use generic instrument for the
clinical assessment of perceived health outcomes in
various settings, as well as for health-economic
evaluations enabling the transformation of out-
comes in QALYs (8,15). Moreover, it has been widely
used for the investigation of HRQOL in diabetic
patients with foot ulcers (10,14,15). According to
rigorous analysis of all collected EQ-5D data, both
revascularization strategies (SES and PTA) improved
HRQOL at all time-points compared with baseline, up
to 1 year of follow-up. Interestingly, in line with the
wound healing outcomes, a trend was noted when
analyzing the quality-of-life metrics provided by the
weighted score when combining all EQ-5D domains.
Improvement of HRQOL outcome measures over time
was markedly more pronounced in the SES group.
Furthermore, in head-to-head comparisons of both
the overall study arms and the wound cohort sub-
groups, there was a stronger numerical beneﬁt of
QALYs gained in the case of SES-treated subjects. The
trend of improvement seemed to be even more pro-
nounced in the case of participants with wounds at
baseline with nearly twice as much a relative gain of
QALYs compared with the complete dataset analysis.
Up to 1 year, use of SES produced a relative gain of
0.10 QALYs (p ¼ 0.08) when examining the wholerandomized trial and 0.17 QALYs (p ¼ 0.09) when
comparing the wound subcohorts separately. Argu-
ably, the trial was not a priori adequately powered for
quality-of-life changes.
Still, our ﬁndings compare favorably with other
HRQOL reports following peripheral angioplasty. For
example, in the SUPER (SMART stent versus balloon
angioplasty in long superﬁcial femoral artery lesions)
study that investigated stenting of the superﬁcial
femoral artery, each event of TLR related to a 0.17
reduction of the HRQOL utility score (16). Similarly, in
the BASIL (Bypass versus Angioplasty in Severe
Ischaemia of the Leg) trial that randomized femo-
ropopliteal bypass versus angioplasty for severe leg
ischemia, the HRQOL utility score improved by 0.30
in the angioplasty group and 0.34 in the bypass sur-
gery group up to 1 year (8); by comparison, in the
ACHILLES trial, the utility scores improved by 0.13 in
the SES arm (0.22 in the SES wound subgroup) and
only 0.03 in the PTA arm (0.06 in the PTA wound
subgroup).
Although there is no analogous trial comparing
wound healing outcomes and HRQOL metrics
following different infrapopliteal revascularization
strategies, these results are in accord with previously
published data indicating that poor diabetic ulcer
prognosis is associated with reduced HRQOL and that
the self-assessment of quality of life score in patients
with foot ulcers is lower compared with that reported
from patients with healed foot ulcers (11,12,14).
Therefore, future randomized trials should include
PROMS, especially in the case of critical limb ischemia
patients. Quality-of-life metrics and cost-utility ana-
lyses will be important in demonstrating a more
pragmatic clinically relevant beneﬁt in this very
morbid patient population.
STUDY LIMITATIONS. First, one limitation is the use
of a single HRQOL instrument for the evaluation of
perceived quality of life. However, the EQ-5D has
been reported to provide reliable data regarding the
health status of peripheral artery disease patients,
whereas other analogous instruments such as the
Short Form-36 (SF-36) do not permit calculations of
QALYs for health-economic assessments. Further-
more, the use of additional tests would complicate
the self-assessment process and could further in-
crease attrition rates (8). Second, the ACHILLES trial
was designed and powered using 1-year angiographic
in-segment binary restenosis as the primary
endpoint. Hence, the trial was not adequately pow-
ered for wound healing and quality-of life metrics,
and this might explain why some of the results had a
trend towards signiﬁcance but did not cross the
PERSPECTIVES
WHAT IS KNOWN? The ACHILLES randomized trial has previ-
ously shown that sirolimus-eluting stents may achieve lower
vessel restenosis and higher event-free survival rates compared
with plain balloon angioplasty for infrapopliteal lesions.
WHAT IS NEW? We reported the HRQOL changes and quality-
adjusted life-years gain in the 2 treatment arms of the ACHILLES
multicenter randomized trial. We have demonstrated that infra-
popliteal sirolimus-eluting stents accelerate wound healing and
may improve quality-of-life metrics compared with plain balloon
angioplasty.
WHAT IS NEXT? More appropriately powered randomized tri-
als are necessary to further investigate the clinical utility and
cost-effectiveness of below-knee drug-eluting stents for critical
limb ischemia treatment.
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267p < 0.05 threshold. Finally, the study did not include
a priori collection of cost data, and therefore, a com-
plete incremental cost-effectiveness analysis was
not feasible.
CONCLUSIONS
Wound healing and HRQOL analysis from the
ACHILLES prospective randomized controlled trial
suggests that revascularization of infrapopliteal
lesions with SES placement may improve wound
healing and quality-of-life metrics compared with
PTA.
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